Alterity Presents Positive ATH434 Data at 2025 MDS Congress
Released
Released
Announcement PDF
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the
2025 International Congress of Parkinson’s Disease and Movement Disorders
– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –
– New analysis increases overall confidence in the Phase 2 trial results –
– State-of-the-art neuroimaging and biomarker analysis advance understanding of MSA
diagnosis –
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 9 October 2025: Alterity Therapeutics
(ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated
to developing disease modifying treatments for neurodegenerative diseases, today
announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in
Multiple System Atrophy (MSA) was featured at the 2025 International Congress of Parkinson’s
Disease and Movement Disorders (MDS) that took place in Honolulu, HI, USA.
“The aggregate data from our double-blind trial continue to demonstrate the potential of ATH434
as a disease modifying therapy for MSA,” said David Stamler, M.D., Chief Executive Officer of
Alterity. “The positive data from our ATH434-201 trial have demonstrated a slowing of disease
progression and stabilization of orthostatic hypotension, one of the most challenging MSA
symptoms to manage. The MDS conference gave us the opportunity to present new analyses
from our double-blind Phase 2 trial that increase our overall confidence in ATH434. When we
accounted for baseline differences in an important predictor of disease progression, the efficacy
signal at the 75 mg dose strengthened meaningfully on the key clinical endpoint of UMSARS I1 at
52 weeks. This new analysis continues to support our belief that ATH434 has great potential to
treat this devastating disease.”
“In addition, we presented data assessing the state-of-the-art neuroimaging and biomarkers
employed in our trial to refine the diagnosis of MSA and track the evolution of the disease across
the two main clinical phenotypes, MSA-P and MSA-C. We remain committed to advancing
ATH434 to the next stage of development while striving to become the market leader dedicated
to improving the overall treatment paradigm for MSA,” concluded Dr. Stamler.
Presentation Highlights:
ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy
Presenter: David Stamler, M.D., Chief Executive Officer, Alterity
Dr. Stamler’s oral platform presentation provided results from the ATH434-201 trial with new
analyses related to orthostatic hypotension (OH), one of the most debilitating MSA symptoms.
Clinical endpoints were analyzed in the clinical analysis population (n=71) that included patients
randomized to treatment who had at least one post-baseline assessment of the key clinical
endpoint, the UMSARS I. There were three arms in the trial comparing two dose levels of ATH434
50 mg (n=25) and 75 mg (n=24) to placebo (n=22), all of which were administered twice daily.
Treatment with ATH434 resulted in a clinically significant reduction in disease severity relative to
placebo on the modified UMSARS I activities of daily living scale at both dose levels, with a 48%
relative treatment effect at the 50 mg dose (p=0.02)2 and a 30% relative treatment effect at the
75 mg dose at 52 weeks. UMSARS I is the key outcome measure of interest to regulatory
authorities such as the FDA.
The presentation described additional analysis regarding OH, which is a form of low blood
pressure that occurs when a person stands up from a sitting or lying position, resulting in
symptoms like dizziness, lightheadedness, or fainting. It is defined as a sustained decrease in
systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm
Hg within three minutes of standing.
Because baseline data revealed that severe OH was substantially higher in the 75 mg group
(29.2% vs 4% in 50 mg and 4.5% in placebo) at enrollment, a new analysis of the USMARS I was
conducted that included the baseline OH systolic blood pressure change as a covariate. When
this variable was included in the analysis of the UMSARS I at 52 weeks, the efficacy signal in 75
mg dose group strengthened to -2.8 points for a relative treatment effect of 35%. This baseline
difference in severe OH largely explains the different responses in 50 mg and 75 mg treatment
groups. Notably, ATH434 demonstrated a beneficial effect on OH symptoms as assessed with the
OH Symptom Assessment, a patient reported outcome. On this scale, placebo patients worsened
on average by approximately 6 points over 52 weeks whereas the 50 mg and 75 mg groups were
stable over the same period of time.
Additional efficacy assessments showed improvement consistent with the UMSARS I findings.
The Clinical Global Impression of Severity Scale3 demonstrated improvement compared to
placebo at both dose levels, with difference at 50 mg achieving statistical significance (p=0.009).
Increased activity in the outpatient setting, as measured by wearable movement sensors, was
observed at both dose levels as compared to placebo, with clinically meaningful improvements
in step count, total walking time, bouts of walking, and total standing time. Regarding
neuroimaging data in 61 participants, ATH434 demonstrated target engagement by reducing iron
accumulation at both dose levels compared to placebo in the globus pallidus, and in the putamen
and substantia nigra at the 50 mg dose level. In addition, ATH434 demonstrated trends in
reducing brain atrophy at both dose levels compared to placebo. ATH434 was well tolerated with
similar adverse event rates compared to placebo and no serious or severe adverse events
attributed to ATH434.
Relationship Between Alpha-Synuclein Aggregation Profiles, Imaging Biomarkers, and Disease
Severity in a Phase 2 Study of ATH434 in MSA
Presenter: Margaret Bradbury, Ph.D., Vice President, Research and Nonclinical Development,
Alterity
As a Parkinsonian disorder, MSA shares several symptoms with Parkinson’s disease that can
hamper accurate diagnoses and differentiation between the two diseases. Alterity’s ATH434-201
trial provides an opportunity to compare α-synuclein aggregation profiles, imaging biomarkers,
and disease severity at baseline to inform future patient selection. In Dr. Bradbury’s presentation
the imaging biomarkers utilized in the ATH434-201 trial presented supportive features of MSA in
96.1% of the 77 enrolled subjects as compared to 78.9% for α-synuclein aggregation profiles in
cerebrospinal fluid (CSF) alone (60 of 76). Of the 11 participants with an α-synuclein aggregation
profile consistent with Parkinson’s disease and/or dementia with Lewy bodies, 80%
demonstrated supportive imaging features of MSA. Two of the 5 participants without evidence
of α-synuclein aggregation had imaging consistent with MSA. Therefore, the presentation
concludes that a multimodal approach combining α-synuclein aggregation profiles with clinical
and imaging data may enhance diagnostic accuracy in MSA.
Differences Between Clinical and Imaging Phenotypes in Phase 2 Study of ATH434 in Multiple
System Atrophy
Author: Paula Trujillo, Ph.D., Research Assistant Professor, Department of Neurology, Vanderbilt
University Medical Center
Dr. Trujillo’s presentation assessed the two main clinical phenotypes of MSA in Alterity’s ATH434-
201 trial: the parkinsonian (MSA-P, n=47) and cerebellar (MSA-C, n=25). The clinical subtypes
were assigned by the site investigators and were compared with multiple neuroimaging
assessments including MRI, quantitative susceptibility mapping (QSM) to measure brain iron, and
automated segmentation to measure brain atrophy. The results show that quantitative MRI
largely complements clinical classification (90% concordance), reinforcing its role as an objective
biomarker. The observed discordance (10%) suggests MRI may capture underlying pathology not
evident clinically, highlighting its value in refining diagnosis and tracking disease evolution.
Presentations will be available on the Alterity Therapeutics website here.
About ATH434
Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of
pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to
reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance
in the brain in preclinical models. As an iron chaperone, it has excellent potential to treat
Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy
(MSA). Phase 1 studies have demonstrated the agent is well tolerated and achieved brain levels
comparable to efficacious levels in animal models of MSA. Positive results from the randomized,
double-blind, placebo-controlled Phase 2 clinical trial in patients with MSA demonstrated robust
clinical efficacy, target engagement on key biomarkers, and a favorable safety profile. Positive
data from a second Phase 2 open-label biomarker trial in patients with more advanced MSA
reinforced these results. ATH434 has been granted Fast Track Designation by the U.S. Food and
Drug Administration (FDA), and Orphan Drug Designation by the FDA and the European
Commission for the treatment of MSA.
About ATH434-201 Phase 2 Clinical Trial
The ATH434-201 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled
investigation of 12 months treatment with ATH434 in patients with MSA. The study evaluated
the efficacy, safety and pharmacokinetics of ATH434 as well as the effect of ATH434 on
neuroimaging and protein biomarkers. Wearable sensors were employed to evaluate motor
activities outside of the clinic. The study enrolled 77 adults who were randomly assigned to
receive ATH434 50 mg or 75 mg twice daily or matching placebo. The data showed that,
compared to placebo, ATH434 produced clinically and statistically significant improvement on
the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, a functional rating
scale that assesses disability on activities of daily living affected in MSA. Additional efficacy
assessments demonstrated improvement consistent with the positive UMSARS Part I findings
including trends in improved motor performance on the Parkinson’s Plus rating scale, the Clinical
Global Impression of Severity Scale, and the Orthostatic Hypotension Symptom Assessment (a
patient reported outcome). Wearable sensor data indicated that ATH434 also led to increased
activity in an outpatient setting. Biomarkers were used to evaluate potential drug effect and
target engagement relative to placebo. Both dose levels reduced iron accumulation in MSA
affected brain regions with trends in preservation of brain volume. ATH434 was well tolerated
with similar adverse event rates compared to placebo and no serious adverse events attributed
to ATH434. Additional information on the Phase 2 trial can be found by ClinicalTrials.gov
Identifier: NCT05109091.
About Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of
the autonomic nervous system and impaired movement. The symptoms reflect the progressive
loss of function and death of different types of nerve cells in the brain and spinal cord. It is a
rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder
characterized by a variable combination of slowed movement and/or rigidity, autonomic
instability that affects involuntary functions such as blood pressure maintenance and bladder
control, and impaired balance and/or coordination that predisposes to falls. A pathological
hallmark of MSA is the accumulation of the protein α-synuclein within glia, the support cells of
the central nervous system, and neuron loss in multiple brain regions. MSA affects up to 50,000
individuals in the U.S., and while some of the symptoms of MSA can be treated with medications,
currently there are no drugs that are able to slow disease progression and there is no cure.4
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate
future for people living with neurodegenerative diseases. The Company is initially focused on
developing disease modifying therapies in Parkinson’s disease and related disorders. Alterity has
demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-
blind, placebo-controlled Phase 2 clinical trial in participants with Multiple System Atrophy
(MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive
data in its open label Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug
discovery platform generating patentable chemical compounds to treat the underlying pathology
of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s website at
www.alteritytherapeutics.com.
1 UMSARS I: Unified Multiple System Atrophy Rating Scale Part I
2
All p-values are uncorrected
3
Clinical Global Impression of Severity: a clinician assessment of the total picture of the subject including the
impact of the illness on function and level of distress
4
Multiple System Atrophy | National Institute of Neurological Disorders and Stroke (nih.gov)
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Contacts:
Investors
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of
the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company
has tried to identify such forward-looking statements by use of such words as "expects,"
"intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and
other similar expressions, but these words are not the exclusive means of identifying such
statements.
Important factors that could cause actual results to differ materially from those indicated by
such forward-looking statements are described in the sections titled “Risk Factors” in the
Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as
reports on Form 6-K, including, but not limited to the following: statements relating to the
Company's drug development program, including, but not limited to the initiation, progress and
outcomes of clinical trials of the Company's drug development program, including, but not
limited to, ATH434, and any other statements that are not historical facts. Such statements
involve risks and uncertainties, including, but not limited to, those risks and uncertainties
relating to the difficulties or delays in financing, development, testing, regulatory approval,
production and marketing of the Company’s drug components, including, but not limited to,
ATH434, the ability of the Company to procure additional future sources of financing,
unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug
compounds, including, but not limited to, ATH434, that could slow or prevent products coming
to market, the uncertainty of obtaining patent protection for the Company's intellectual
property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights
and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information
currently available to us and speaks only as of the date on which it is made. We undertake no
obligation to publicly update any forward-looking statement, whether written or oral, that may
be made from time to time, whether as a result of new information, future developments or
otherwise.
Share your feedback
Discover